A phylogeny-free microbiome dysbiosis detection pipeline for non-invasive disease diagnosis

2017 ◽  
Author(s):  
O. Ufuk Nalbantoglu ◽  
A. Emre Onuk
Keyword(s):  
Disease Diagnosis ◽  
Invasive Disease ◽  
Non Invasive

scholarly journals Socio-economic demands and challenges for non-invasive disease diagnosis through a portable breathalyzer by the incorporation of 2D nanosheets and SMO nanocomposites

RSC Advances ◽  
2021 ◽  
Vol 11 (35) ◽  
pp. 21216-21234
Author(s):  
Ramji Kalidoss ◽  
Radhakrishnan Kothalam ◽  
A. Manikandan ◽  
Saravana Kumar Jaganathan ◽  
Anish Khan ◽  
...  
Keyword(s):  
Breath Analysis ◽  
Disease Diagnosis ◽  
Invasive Disease ◽  
Research Community ◽  
Clinical Diagnostics ◽  
Non Invasive ◽  
Technological Developments ◽  
2D Nanosheets

Breath analysis for non-invasive clinical diagnostics and treatment progression has penetrated the research community owing to the technological developments in novel sensing nanomaterials.

scholarly journals Advanced Biomimetic Nanomaterials for Non-invasive Disease Diagnosis

2021 ◽  
Vol 8 ◽  
Author(s):  
Zhiyuan Feng ◽  
Hao Fan ◽  
Lin Cheng ◽  
Huan Zhang ◽  
Hong Fan ◽  
...  
Keyword(s):  
Social Stress ◽  
Large Scale ◽  
Metabolic Diseases ◽  
Disease Diagnosis ◽  
Invasive Disease ◽  
Non Invasive ◽  
Disease Marker ◽  
Medical Materials ◽  
Biomimetic Nanomaterials ◽  
Marker Detection

In modern society, the incidence of cancer, inflammatory diseases, nervous system diseases, metabolic diseases, and cardiovascular diseases is on the rise. These diseases not only cause physical and mental suffering for patients, but also place an enormous burden on society. Early, non-invasive diagnosis of these diseases can reduce the physical and mental pain of patients and social stress. There is an urgent need for advanced materials and methods for non-invasive disease marker detection, large-scale disease screening, and early diagnosis. Biomimetic medical materials are synthetic materials designed to be biocompatible or biodegradable, then developed for use in the medical industry. In recent years, with the development of nanotechnology, a variety of biomimetic medical materials with advanced properties have been introduced. Biomimetic nanomaterials have made great progress in biosensing, bioimaging, and other fields. The latest advance of biomimetic nanomaterials in disease diagnosis has attracted tremendous interest. However, the application of biomimetic nanomaterials in disease diagnosis has not been reviewed. This review particularly focuses on the potential of biomimetic nanomaterials in non-invasive disease marker detection and disease diagnosis. The first part focuses on the properties and characteristics of different kinds of advanced biomimetic nanomaterials. In the second part, the recent cutting-edge methods using biosensors and bioimaging based on biomimetic nanomaterials for non-invasive disease diagnosis are reviewed. In addition, the existing problems and future development of biomimetic nanomaterials is briefly described in the third part. The application of biomimetic nanomaterials would provide a novel and promising diagnostic method for non-invasive disease marker detection, large-scale clinical screening, and diagnosis, promoting the exploitation of devices with better detection performance and the development of global clinical public health.

scholarly journals Next-Generation Biomarkers for Cholangiocarcinoma

Cancers ◽  
2021 ◽  
Vol 13 (13) ◽  
pp. 3222
Author(s):  
Pedro M. Rodrigues ◽  
Arndt Vogel ◽  
Marco Arrese ◽  
Domingo C. Balderramo ◽  
Juan W. Valle ◽  
...  
Keyword(s):  
Biomarker Discovery ◽  
Tumor Development ◽  
Predictive Biomarkers ◽  
Disease Diagnosis ◽  
Future Research ◽  
Tumor Biopsy ◽  
Non Invasive ◽  
Tumor Stages ◽  
At Risk Populations ◽  
Early Tumor

The increasing mortality rates of cholangiocarcinoma (CCA) registered during the last decades are, at least in part, a result of the lack of accurate non-invasive biomarkers for early disease diagnosis, making the identification of patients who might benefit from potentially curative approaches (i.e., surgery) extremely challenging. The obscure CCA pathogenesis and associated etiological factors, as well as the lack of symptoms in patients with early tumor stages, highly compromises CCA identification and to predict tumor development in at-risk populations. Currently, CCA diagnosis is accomplished by the combination of clinical/biochemical features, radiological imaging and non-specific serum tumor biomarkers, although a tumor biopsy is still needed to confirm disease diagnosis. Furthermore, prognostic and predictive biomarkers are still lacking and urgently needed. During the recent years, high-throughput omics-based approaches have identified novel circulating biomarkers (diagnostic and prognostic) that might be included in large, international validation studies in the near future. In this review, we summarize and discuss the most recent advances in the field of biomarker discovery in CCA, providing new insights and future research directions.

Virus induced hepatocellular carcinoma (HCC) and protein biomarkers

2021 ◽  
Author(s):  
Hamza Abbas Jaffari ◽  
Sumaira Mazhar
Keyword(s):  
Hepatocellular Carcinoma ◽  
Early Stage ◽  
Imaging Techniques ◽  
Disease Diagnosis ◽  
Protein Biomarkers ◽  
Early Disease ◽  
Detection Systems ◽  
Non Invasive ◽  
Viral Hepatitis B ◽  
Current Article

Hepatocellular carcinoma (HCC) is a standout amongst the most widely recognized cancers around the world, and just as the alcoholic liver disease it is also progressed by extreme viral hepatitis B or C. At the early stage of the disease, numerous patients are asymptomatic consequently late diagnosis of HCC occurs resulting in expensive surgical resection or transplantation. On the basis of the alpha fetoprotein (AFP) estimation, combined with the ultrasound and other sensitive imaging techniques used, the non-invasive detection systems are available. For early disease diagnosis and its use in the effective treatment of HCC patients, the identification of HCC biomarkers has provided a breakthrough utilizing the molecular genetics and proteomics. In the current article, most recent reports on the protein biomarkers of HBV or HCV-related HCC and their co-evolutionary association with liver cancer are reviewed.

scholarly journals Alterations of human lung and gut microbiome in non-small cell lung carcinomas and distant metastasis

2020 ◽  
Author(s):  
Hui Lu ◽  
Na L. Gao ◽  
Chunhua Wei ◽  
Jiaojiao Wang ◽  
Fan Tong ◽  
...  
Keyword(s):  
Distant Metastasis ◽  
Mixed Models ◽  
Area Under The Curve ◽  
Disease Diagnosis ◽  
Invasive Disease ◽  
Small Cell ◽  
Small Cell Lung ◽  
Microbial Biomarkers ◽  
Distinct Disease ◽  
Nsclc Patients

AbstractBackgroundNon-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths worldwide. Although dysbiosis of lung and gut microbiota have been associated with NSCLC, their relative contributions are unclear; in addition, their roles in distant metastasis (DM) are still illusive.ResultsWe surveyed the fecal and sputum (as a proxy for lung) microbiota in healthy controls and NSCLC patients of various stages, and found significant perturbations of gut- and sputum-microbiota in patients with NSCLC and DM. Machine-learning models combining both microbiota (mixed models) performed better than either dataset in patient stratification, with the highest area under the curve (AUC) value of 0.842. Sputum-microbiota contributed more than the gut in the mixed models; in addition, sputum-only models performed similarly to the mixed models in most cases. Several microbial-biomarkers were shared by both microbiota, indicating their similar roles at distinct body sites. Microbial-biomarkers of distinct disease stages were mostly shared, suggesting biomarkers for distant metastasis could be acquired early. Furthermore, Pseudomonas aeruginosa, a species previously associated with wound infections, was significantly more abundant in brain metastasis, indicating distinct types of DMs could have different microbial-biomarkers.ConclusionOur results indicate that alterations of sputum-microbiota have stronger relationships with NSCLC and distant metastasis than the gut, and strongly support the feasibility of metagenome-based non-invasive disease diagnosis and risk evaluation.

Novel scheme for non-invasive gut bioinformation acquisition with a magnetically controlled sampling capsule endoscope

Gut ◽  
2021 ◽  
pp. gutjnl-2020-322465
Author(s):  
Zhen Ding ◽  
Weijun Wang ◽  
Kun Zhang ◽  
Fanhua Ming ◽  
Tianyi Yangdai ◽  
...  
Keyword(s):  
Hippuric Acid ◽  
Metabolic Diseases ◽  
Intestinal Flora ◽  
Disease Diagnosis ◽  
Magnetic Control ◽  
Capsule Endoscope ◽  
Direct Visualization ◽  
Dramatic Decrease ◽  
Non Invasive ◽  
Microbiome Profiling

ObjectiveIntestinal flora and metabolites are associated with multiple systemic diseases. Current approaches for acquiring information regarding microbiota/metabolites have limitations. We aimed to develop a precise magnetically controlled sampling capsule endoscope (MSCE) for the convenient, non-invasive and accurate acquisition of digestive bioinformation for disease diagnosis and evaluation.DesignThe MSCE and surgery were both used for sampling both jejunal and ileal GI content in the control and antibiotic-induced diarrhoea groups. The GI content was then used for microbiome profiling and metabolomics profiling.ResultsCompared with surgery, our data showed that the MSCE precisely acquired data regarding the intestinal flora and metabolites, which was effectively differentiated in different intestinal regions and disease models. Using MSCE, we detected a dramatic decrease in the abundance of Bacteroidetes, Patescibacteria and Actinobacteria and hippuric acid levels, as well as an increase in the abundance of Escherichia–Shigella and the 2-pyrrolidinone levels were detected in the antibiotic-induced diarrhoea model by MSCE. MSCE-mediated sampling revealed specific gut microbiota/metabolites including Enterococcus, Lachnospiraceae, acetyl-L-carnitine and succinic acid, which are related to metabolic diseases, cancers and nervous system disorders. Additionally, the MSCE exhibited good sealing characteristics with no contamination after sampling.ConclusionsWe present a newly developed MSCE that can non-invasively and accurately acquire intestinal bioinformation via direct visualization under magnetic control, which may further aid in disease prevention, diagnosis, prognosis and treatment.

Sign in / Sign up

Export Citation Format

Share Document